{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:05:07Z","timestamp":1773680707996,"version":"3.50.1"},"reference-count":47,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare variant of HL that accounts for 5% of all HL cases. The expression of CD20 on neoplastic lymphocytes provides a suitable target for novel treatments based on Rituximab. Due to its rarity, consolidated and widely accepted treatment guidelines are still lacking for this disease. Methods: Between 1 December 2007 and 28 February 2018, sixteen consecutive newly diagnosed adult patients with NLPHL received Rituximab (induction \u00b1 maintenance)-based therapy, according to the baseline risk of German Hodgkin Study Group prognostic score system. The treatment efficacy and safety of the Rituximab-group were compared to those of a historical cohort of 12 patients with NLPHL who received Doxorubicin, Bleomycin, Vinblastine, Dacarbazine (ABVD) chemotherapy followed by radiotherapy (RT), if needed, according to a similar baseline risk. The primary outcome was progression-free survival (PFS) and secondary outcomes were overall survival (OS) and side-effects (according to the Common Terminology Criteria for Adverse Events, v4.03). Results: After a 7-year follow-up (range, 1\u201311 years), PFS was 100% for patients treated with the Rituximab-containing regimen versus 66% for patients of the historical cohort (p = 0.036). Four patients in the latter group showed insufficient response to therapy. The PFS for early favorable and early unfavorable NLPHLs was similar between treatment groups, while a better PFS was recorded for advanced-stages treated with the Rituximab-containing regimen. The OS was similar for the two treatment groups. Short- and long-term side-effects were more frequently observed in the historical cohort. Grade \u22653 neutropenia was more frequent in the historical cohort compared with the Rituximab-group (58.3% vs. 18.7%, respectively; p = 0.03). Long-term non-hematological toxicities were observed more frequently in the historical cohort. Conclusion: Our results confirm the value of Rituximab in NLPHL therapy and show that Rituximab (single-agent) induction and maintenance in a limited-stage, or Rituximab with ABVD only in the presence of risk factors, give excellent results while sparing cytotoxic agent- and\/or RT-related damage. Furthermore, Rituximab inclusion in advanced-stage therapeutic strategy seems to improve PFS compared to conventional chemo-radiotherapy.<\/jats:p>","DOI":"10.3390\/cancers13081760","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T11:31:59Z","timestamp":1617795119000},"page":"1760","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2714-5109","authenticated-orcid":false,"given":"Novella","family":"Pugliese","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Section, University of Naples \u201cFederico II\u201d, Via Sergio Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8508-2524","authenticated-orcid":false,"given":"Marco","family":"Picardi","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Section, University of Naples \u201cFederico II\u201d, Via Sergio Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5641-231X","authenticated-orcid":false,"given":"Roberta","family":"Della Pepa","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Section, University of Naples \u201cFederico II\u201d, Via Sergio Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3943-4263","authenticated-orcid":false,"given":"Claudia","family":"Giordano","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Section, University of Naples \u201cFederico II\u201d, Via Sergio Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Muriano","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Section, University of Naples \u201cFederico II\u201d, Via Sergio Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo","family":"Leone","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Section, University of Naples \u201cFederico II\u201d, Via Sergio Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Delle Cave","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Section, University of Naples \u201cFederico II\u201d, Via Sergio Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-4874","authenticated-orcid":false,"given":"Alessandro","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Section, University of Naples \u201cFederico II\u201d, Via Sergio Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violetta","family":"Marafioti","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Section, University of Naples \u201cFederico II\u201d, Via Sergio Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Gabriella","family":"Rascato","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Section, University of Naples \u201cFederico II\u201d, Via Sergio Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Russo","sequence":"additional","affiliation":[{"name":"Pathology Unit, Department of Advanced Biomedical Sciences, University of Naples \u201cFederico II\u201d, Via Sergio Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2576-220X","authenticated-orcid":false,"given":"Massimo","family":"Mascolo","sequence":"additional","affiliation":[{"name":"Pathology Unit, Department of Advanced Biomedical Sciences, University of Naples \u201cFederico II\u201d, Via Sergio Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Hematology Section, University of Naples \u201cFederico II\u201d, Via Sergio Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-Predominant and Classical Hodgkin\u2019s Lymphoma: A Comprehensive analysis from the German Hodgkin study group","volume":"26","author":"Reineke","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin\u2019s Disease and lymphocyte-rich classical Hodgkin\u2019s Disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin\u2019s Disease","volume":"17","author":"Diehl","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","article-title":"Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Hoppe","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s Disease: Long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","article-title":"Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: Long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)","volume":"111","author":"Schulz","year":"2008","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/blood-2018-02-836437","article-title":"Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: An analysis from the German Hodgkin Study Group","volume":"132","author":"Eichenauer","year":"2018","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","article-title":"Rituximab in lymphocyte-predominant Hodgkin disease: Results of a phase 2 trial","volume":"101","author":"Ekstrand","year":"2003","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","article-title":"Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group","volume":"118","author":"Eichenauer","year":"2011","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/bjh.14856","article-title":"Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma","volume":"182","author":"Picardi","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","article-title":"Mature results of a phase II study of rituximab therapy for nodular lymphocyte\u2013predominant hodgkin lymphoma","volume":"32","author":"Advani","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A Prognostic score for advanced Hodgkin\u2019s Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1182\/asheducation-2003.1.225","article-title":"Hodgkin\u2019s Lymphoma: Biology and treatment strategies for primary, refractory, and relapsed disease","volume":"2003","author":"Diehl","year":"2003","journal-title":"Hematology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3109\/10428194.2011.584993","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: Evidence from 14-year follow-up in the West of Scotland Cancer Network","volume":"52","author":"Farrell","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/cncr.10404","article-title":"European Organization for Research and Treatment of Cancer and Groupe d\u2019Etude des Lymphomes de l\u2019Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease","volume":"94","author":"Wilder","year":"2002","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2004-02-0567","article-title":"Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation","volume":"104","author":"Feugier","year":"2004","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/annonc\/mdi323","article-title":"Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin\u2019s lymphoma: A retrospective analysis from the German Hodgkin Study Group (GHSG)","volume":"16","author":"Reineke","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","article-title":"Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: A retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group","volume":"104","author":"Wirth","year":"2005","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early-stage, lymphocyte-predominant Hodgkin\u2019s Lymphoma: Patient outcomes from a large, single-institution series with long follow-up","volume":"28","author":"Chen","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1182\/blood-2011-07-365932","article-title":"Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome","volume":"118","author":"Savage","year":"2011","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.2014.60.4363","article-title":"Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin Lymphoma: A report from the German Hodgkin Study Group","volume":"33","author":"Eichenauer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1200\/JCO.2018.36.15_suppl.7535","article-title":"Limited stage nodular lymphocyte predominant Hodgkin lymphoma (NLPHL): A subgroup analysis of the HD.6 clinical trial","volume":"36","author":"Monteith","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/cam4.1383","article-title":"Adult nodular lymphocyte-predominant Hodgkin lymphoma: Treatment modality utilization and survival","volume":"7","author":"Alonso","year":"2018","journal-title":"Cancer Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/bloodadvances.2018029140","article-title":"Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma","volume":"3","author":"Pinnix","year":"2019","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood-2018-10-877761","article-title":"Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"133","author":"Borchmann","year":"2019","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bjh.16290","article-title":"Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: A population-based analysis in the Netherlands, 1993\u20132016","volume":"189","author":"Posthuma","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/s41375-019-0609-3","article-title":"Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: Long-term follow-up of a phase 2 study from the German Hodgkin Study Group","volume":"34","author":"Eichenauer","year":"2020","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1182\/blood.2019003877","article-title":"Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: A multi-institutional study of adult patients by ILROG","volume":"135","author":"Binkley","year":"2020","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1182\/blood-2013-12-541078","article-title":"Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: A matched pair outcome analysis","volume":"123","author":"Xing","year":"2014","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1182\/blood.V126.23.3863.3863","article-title":"Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) vs. classical Hodgkin Lymphoma (cHL) at Princess Margaret Cancer Centre","volume":"126","author":"Ames","year":"2015","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/bjh.12055","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents\u2014A comprehensive review of biology, clinical course and treatment options","volume":"159","author":"Shankar","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood-2017-02-766121","article-title":"Encouraging activity for R-CHOP in advanced stage nodular lymphocyte\u2013predominant Hodgkin lymphoma","volume":"130","author":"Fanale","year":"2017","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1080\/0284186X.2018.1450522","article-title":"R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma","volume":"57","author":"Prusila","year":"2018","journal-title":"Acta Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1200\/JCO.19.00986","article-title":"Long-term follow-up of patients with Nodular Lymphocyte-Predominant Hodgkin Lymphoma treated in the HD7 to HD15 trials: A report from the German Hodgkin Study Group","volume":"38","author":"Eichenauer","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Eichenauer, D., Kreissl, S., B\u00fchnen, I., Baues, C., Kobe, C., van Heek, L., Goergen, H., Fuchs, M., Hartmann, S., and von Tresckow, B. (2021). PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: A subgroup analysis of the randomized German Hodgkin Study Group HD18 study. Ann. Oncol., 21.","DOI":"10.1016\/j.annonc.2021.02.018"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1200\/JCO.2009.26.3293","article-title":"What is the appropriate systemic chemotherapy for Lymphocyte-Predominant Hodgkin\u2019s Lymphoma?","volume":"28","author":"Canellos","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2009.24.9516","article-title":"Transformation to Aggressive Lymphoma in Nodular Lymphocyte-Predominant Hodgkin\u2019s Lymphoma","volume":"28","author":"Connors","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3324\/haematol.2015.133025","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma: A Lymphoma Study Association retrospective study","volume":"100","author":"Lazarovici","year":"2015","journal-title":"Haematologia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1182\/blood.2019004044","article-title":"How I treat nodular lymphocyte-predominant Hodgkin lymphoma","volume":"136","author":"Eichenauer","year":"2020","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/1097-0142(196603)19:3<317::AID-CNCR2820190304>3.0.CO;2-O","article-title":"Natural history of Hodgkin\u2019s disease as related to its pathologic picture","volume":"19","author":"Lukes","year":"1966","journal-title":"Cancer"},{"key":"ref_42","unstructured":"Vardiman, J., Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3324\/haematol.2008.002451","article-title":"Classical Hodgkin\u2019s lymphoma in adults: Guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up","volume":"94","author":"Brusamolino","year":"2009","journal-title":"Haematologica"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised Response Criteria for Malignant Lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1148\/radiol.14132154","article-title":"Advanced-stage Hodgkin lymphoma: US\/chest radiography for detection of relapse in patients in first complete remission\u2014A randomized trial of routine surveillance imaging procedures","volume":"272","author":"Picardi","year":"2014","journal-title":"Radiology"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/8\/1760\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:34:14Z","timestamp":1760362454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/8\/1760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["cancers13081760"],"URL":"https:\/\/doi.org\/10.3390\/cancers13081760","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]}}}